Aurora Cannabis Reveals Latest Product Innovations: Ultra-High Potency Indicas And Strains For Veterans

Aurora Cannabis Inc. ACB ACB, announced on Tuesday developments in cannabis science from Aurora’s research and genetics facility, Aurora Coast.

The latest innovations from the Canadian medical cannabis giant include:

• Aurora | CBD Varius (1g, 510 Cartridge);
• MedReleaf (Strains For Heroes) | Esprit De Corps (5g and 15g); a premium sativa (THC: 20-29%, CBD: 0-1%), developed under the Strains For Heroes initiative by Aurora with direct feedback from Veteran patients;
• MedReleaf | Sedamen (1g, 510 Cartridge) in a higher THC format;
• MedReleaf | Noculus (5g and 15g); an ultra-high potency indica, featuring THC levels between 25-31% and CBD content from 0-1%; and
• WMMC | Seasonal Stash – Frosted Alpine (10g); a limited-grown hybrid strain (THC: 24-30%; CBD: 0-1%).

Read Also: Aurora Cannabis Launches Innovative THC Oil Products In Australia To Meet Diverse Patient Needs

• Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.

“As a company committed to leading the way in terms of cannabis innovation, we are dedicated to putting patients first by harnessing the innovative solutions developed by our top researchers at Aurora Coast, our unique global research facility,” Lana Culley, vice president of science and innovation at Aurora. “We strive to continuously raise the bar on product superiority and overall user experience so that we can deliver on our mission of providing patients with access to the very best medical cannabis.”

The latest update from Aurora comes on the heels of its recently revealed lineup of innovations from Greybeard, San Rafael '71 and Tasty's brands for Canadian consumers.

Aurora reported its second quarter financial results, showing revenue of CA$81.1 million ($58.3 million), up from CA$63.1 million in the same period last year.

The company attributed the 29% increase from the prior period to 41% growth in its global medical cannabis business and 21% growth in its plant propagation business, slightly offset by lower quarterly revenue in its consumer cannabis business.

Read Next:

• UK Medical Cannabis Market Gets Boost With Aurora And Script Assist Collaboration

ACB Price Action

Aurora's shares traded 3.28% lower at $4.42 per share at the time of writing on Tuesday morning.